Tenaya Therapeutics Inc (NASDAQ:TNYA) has a beta value of 2.74 and has seen 2.29 million shares traded in the last trading session. The company, currently valued at $228.16M, closed the last trade at $2.88 per share which meant it gained $0.13 on the day or 4.73% during that session. The TNYA stock price is -143.4% off its 52-week high price of $7.01 and 44.1% above the 52-week low of $1.61. If we look at the company’s 10-day average daily trading volume, we find that it stood at 4.44 million shares traded. The 3-month trading volume is 3.16 million shares.
The consensus among analysts is that Tenaya Therapeutics Inc (TNYA) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.31.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Tenaya Therapeutics Inc (NASDAQ:TNYA) trade information
Sporting 4.73% in the green in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the TNYA stock price touched $2.88 or saw a rise of 28.18%. Year-to-date, Tenaya Therapeutics Inc shares have moved -11.11%, while the 5-day performance has seen it change -23.81%. Over the past 30 days, the shares of Tenaya Therapeutics Inc (NASDAQ:TNYA) have changed 42.57%. Short interest in the company has seen 14.05 million shares shorted with days to cover at 2.31.
Tenaya Therapeutics Inc (TNYA) estimates and forecasts
Figures show that Tenaya Therapeutics Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -12.73% over the past 6 months, with this year growth rate of 19.64%, compared to 16.90% for the industry. Revenue growth from the last financial year stood is estimated to be 0.00%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -27.43% over the past 5 years.
TNYA Dividends
Tenaya Therapeutics Inc is expected to release its next earnings report in January this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Tenaya Therapeutics Inc (NASDAQ:TNYA)’s Major holders
Insiders own 1.17% of the company shares, while shares held by institutions stand at 73.76% with a share float percentage of 74.64%. Investors are also buoyed by the number of investors in a company, with Tenaya Therapeutics Inc having a total of 132.0 institutions that hold shares in the company. The top two institutional holders are COLUMN GROUP LLC with over 9.4 million shares worth more than $29.14 million. As of 2024-06-30, COLUMN GROUP LLC held 11.6078% of shares outstanding.
The other major institutional holder is RA CAPITAL MANAGEMENT, L.P., with the holding of over 7.62 million shares as of 2024-06-30. The firm’s total holdings are worth over $23.63 million and represent 9.4124% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Price (T.Rowe) New Horizons Fund and Vanguard Total Stock Market Index Fund . As of Sep 30, 2024 , the former fund manager holds about 2.65% shares in the company for having 2.1 shares of worth $6.05 million while later fund manager owns 2.06 shares of worth $5.95 million as of Sep 30, 2024 , which makes it owner of about 2.61% of company’s outstanding stock.
